XML 44 R31.htm IDEA: XBRL DOCUMENT
v3.19.2

Supplemental data | 6 Months Ended
--- | ---
Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Supplemental data | Supplemental data The following information is presented as supplemental data as required by the indentures governing the Company’s senior notes. Condensed Consolidating Statements of Income
For the six months ended June 30, 2019 |  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
Patient service operating revenues |  | $ | 5,369,217 |  |  | $ | — |  |  | $ | — |  |  | $ | 5,369,217 |
Provision for uncollectible accounts |  | (15,712 | ) |  | — |  |  | — |  |  | (15,712 | )
Net patient service operating revenues |  | 5,353,505 |  |  | — |  |  | — |  |  | 5,353,505 |
Other revenues |  | 232,312 |  |  | — |  |  | — |  |  | 232,312 |
Total net operating revenues |  | 5,585,817 |  |  | — |  |  | — |  |  | 5,585,817 |
Operating expenses |  | 4,783,424 |  |  | — |  |  | — |  |  | 4,783,424 |
Operating income |  | 802,393 |  |  | — |  |  | — |  |  | 802,393 |
Debt expense |  | (275,345 | ) |  | — |  |  | — |  |  | (275,345 | )
Other income |  | 12,583 |  |  | — |  |  | — |  |  | 12,583 |
Income tax expense |  | 132,684 |  |  | — |  |  | — |  |  | 132,684 |
Net income from continuing operations |  | 406,947 |  |  | — |  |  | — |  |  | 406,947 |
Net income from discontinued operations, net of tax |  | 109,697 |  |  | 12,706 |  |  | 249 |  |  | 96,742 |
Net income |  | 516,644 |  |  | 12,706 |  |  | 249 |  |  | 503,689 |
Less: Net income attributable to noncontrolling interests |  | (93,804 | ) |  | (1,255 | ) |  | — |  |  | (92,549 | )
Net income attributable to DaVita Inc. |  | $ | 422,840 |  |  | $ | 11,451 |  |  | $ | 249 |  |  | $ | 411,140 |
(1) | After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Statements of Comprehensive Income
For the six months ended June 30, 2019 |  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
Net income |  | $ | 516,644 |  |  | $ | 12,706 |  |  | $ | 249 |  |  | $ | 503,689 |
Other comprehensive income |  | 1,313 |  |  | — |  |  | — |  |  | 1,313 |
Total comprehensive income |  | 517,957 |  |  | 12,706 |  |  | 249 |  |  | 505,002 |
Less: Comprehensive income attributable to the noncontrolling interests |  | (93,804 | ) |  | (1,255 | ) |  | — |  |  | (92,549 | )
Comprehensive income attributable to DaVita Inc. |  | $ | 424,153 |  |  | $ | 11,451 |  |  | $ | 249 |  |  | $ | 412,453 |
(1) | After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Balance Sheets
As of June 30, 2019 |  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
Cash and cash equivalents |  | $ | 3,575,638 |  |  | $ | — |  |  | $ | — |  |  | $ | 3,575,638 |
Restricted cash and equivalents |  | 106,772 |  |  | — |  |  | — |  |  | 106,772 |
Accounts receivable, net |  | 2,010,801 |  |  | — |  |  | — |  |  | 2,010,801 |
Other current assets |  | 697,418 |  |  | — |  |  | — |  |  | 697,418 |
Total current assets |  | 6,390,629 |  |  | — |  |  | — |  |  | 6,390,629 |
Property and equipment, net |  | 3,405,315 |  |  | — |  |  | — |  |  | 3,405,315 |
Operating lease right-of-use assets |  | 2,790,885 |  |  | — |  |  | — |  |  | 2,790,885 |
Amortizable intangibles, net |  | 120,574 |  |  | — |  |  | — |  |  | 120,574 |
Other long-term assets |  | 358,171 |  |  | — |  |  | — |  |  | 358,171 |
Goodwill |  | 6,865,386 |  |  | — |  |  | — |  |  | 6,865,386 |
Total assets |  | $ | 19,930,960 |  |  | $ | — |  |  | $ | — |  |  | $ | 19,930,960 |
Current liabilities |  | $ | 5,706,944 |  |  | $ | — |  |  | $ | — |  |  | $ | 5,706,944 |
Long-term operating leases liabilities |  | 2,689,249 |  |  | — |  |  | — |  |  | 2,689,249 |
Long-term debt and other long-term liabilities |  | 6,105,965 |  |  | — |  |  | — |  |  | 6,105,965 |
Noncontrolling interests subject to put provisions |  | 1,185,733 |  |  | — |  |  | — |  |  | 1,185,733 |
Total DaVita Inc. shareholders’ equity |  | 4,049,298 |  |  | — |  |  | — |  |  | 4,049,298 |
Noncontrolling interests not subject to put provisions |  | 193,771 |  |  | — |  |  | — |  |  | 193,771 |
Shareholders’ equity |  | 4,243,069 |  |  | — |  |  | — |  |  | 4,243,069 |
Total liabilities and shareholder’s equity |  | $ | 19,930,960 |  |  | $ | — |  |  | $ | — |  |  | $ | 19,930,960 |
(1) | After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Statements of Cash Flows
For the six months ended June 30, 2019 |  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
Cash flows from operating activities: |  |  |  |  |  |  |  |
Net income |  | $ | 516,644 |  |  | $ | 12,706 |  |  | $ | 249 |  |  | $ | 503,689 |
Changes in operating and intercompany assets and liabilities and non-cash items included in net income |  | 234,471 |  |  | (4,607 | ) |  | (249 | ) |  | 239,327 |
Net cash provided by operating activities |  | 751,115 |  |  | 8,099 |  |  | — |  |  | 743,016 |
Cash flows from investing activities: |  |  |  |  |  |  |  |  |  |  |  |
Additions of property and equipment |  | (373,918 | ) |  | (846 | ) |  | — |  |  | (373,072 | )
Acquisitions |  | (65,970 | ) |  | — |  |  | — |  |  | (65,970 | )
Proceeds from asset and business sales |  | 3,851,381 |  |  | — |  |  | — |  |  | 3,851,381 |
Investments and other items |  | (8,801 | ) |  | (1,882 | ) |  | — |  |  | (6,919 | )
Net cash provided by (used in) investing activities |  | 3,402,692 |  |  | (2,728 | ) |  | — |  |  | 3,405,420 |
Cash flows from financing activities: |  |  |  |  |  |  |  |  |  |  |  |
Long-term debt |  | (1,164,109 | ) |  | — |  |  | — |  |  | (1,164,109 | )
Intercompany |  | — |  |  | (247,175 | ) |  | — |  |  | 247,175 |
Other items |  | (146,444 | ) |  | — |  |  | — |  |  | (146,444 | )
Net cash used in financing activities |  | (1,310,553 | ) |  | (247,175 | ) |  | — |  |  | (1,063,378 | )
Effect of exchange rate changes on cash, cash equivalents and restricted cash |  | (77 | ) |  | — |  |  | — |  |  | (77 | )
Net increase (decrease) in cash, cash equivalents and restricted cash |  | 2,843,177 |  |  | (241,804 | ) |  | — |  |  | 3,084,981 |
Less: Net decrease in cash, cash equivalents and restricted cash from discontinued operations |  | (423,813 | ) |  | (241,804 | ) |  | — |  |  | (182,009 | )
Net increase in cash, cash equivalents and restricted cash from continuing operations |  | 3,266,990 |  |  | — |  |  | — |  |  | 3,266,990 |
Cash, cash equivalents and restricted cash of continuing operations at beginning of the year |  | 415,420 |  |  | — |  |  | — |  |  | 415,420 |
Cash, cash equivalents and restricted cash of continuing operations at end of the period |  | $ | 3,682,410 |  |  | $ | — |  |  | $ | — |  |  | $ | 3,682,410 |
(1) After elimination of the unrestricted subsidiaries and the physician groups.

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration